Financial Instruments and Fair Value Measurements (Tables)

12 Months Ended

Sep. 30, 2016

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	September 30, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	34.6	$	23.1	$	11.5	$	—
Foreign exchange forward and option contracts	$	0.2	$	0.2	$	—	$	—
	$	34.8	$	23.3	$	11.5	$	—
Liabilities:
Deferred compensation liabilities	$	26.8	$	—	$	26.8	$	—
Contingent consideration and acquired contingent liabilities	247.8		—		—		247.8
Foreign exchange forward and option contracts	1.6		1.6		—		—
	$	276.2	$	1.6	$	26.8	$	247.8



	September 25, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	34.6	$	24.2	$	10.4	$	—
	$	34.6	$	24.2	$	10.4	$	—
Liabilities:
Deferred compensation liabilities	$	20.0	$	—	$	20.0	$	—
Contingent consideration and acquired contingent liabilities	174.6		—		—		174.6
Foreign exchange forward and option contracts	3.3		3.3		—		—
	$	197.9	$	3.3	$	20.0	$	174.6

Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration



Balance at September 25, 2015	$	174.6
Acquisition date fair value of contingent consideration	106.9
Acquisition date fair value of acquired contingent consideration	10.6
Payments	(55.0		)
Accretion expense	6.3
Fair value adjustment	4.4
Balance at September 30, 2016	$	247.8

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	September 30, 2016				September 25, 2015
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable rate receivable securitization	$	235.0	$	235.0	$	153.0	$	153.0
3.50% notes due April 2018	300.0		299.6		300.0		294.3
4.875% notes due April 2020	700.0		712.4		700.0		684.1
Term loans due March 2021	1,953.5		1,951.8		1,978.5		1,966.5
4.00% term loan due February 2022	7.1		7.1		7.9		7.9
9.50% debentures due May 2022	10.4		12.1		10.4		13.0
5.75% notes due August 2022	884.0		869.3		900.0		876.1
8.00% debentures due March 2023	4.4		4.9		4.4		5.3
4.75% notes due April 2023	600.0		539.5		600.0		539.6
5.625% notes due October 2023	740.0		710.2		750.0		705.2
5.50% notes due April 2025	700.0		663.6		700.0		646.0
Revolving credit facility	—		—		500.0		500.0

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Fiscal Year
	2016		2015		2014
CuraScript, Inc.	38	%	35	%	7	%
McKesson Corporation	12	%	20	%	25	%
AmerisourceBergen Corporation	8	%	10	%	15	%
Cardinal Health, Inc.	7	%	11	%	18	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	September 30, 2016		September 25, 2015
McKesson Corporation	30	%	26	%
AmerisourceBergen Corporation	15	%	13	%
CuraScript, Inc.	14	%	18	%
Cardinal Health, Inc.	10	%	13	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Fiscal Year
	2016		2015		2014
Acthar	34	%	35	%	7	%
Inomax	14	%	6	%	—	%
Acetaminophen products (API)	5	%	7	%	12	%
Methylphenidate ER	3	%	5	%	13	%